Hep D: From Rare to Aware

CHD remains underdiagnosed, with patient identification historically limited by therapeutic options. Yet it’s the most aggressive form of viral hepatitis, with the worst outcomes when untreated. Join an interactive session with leading hepatologists and a person living with CHD to explore the diagnostic journey, care gaps, and evolving treatment landscape. 

Industry Supporter: Mirum Pharmaceuticals